TheraRadar
Data updated: May 26, 2026

KINEVAC (sincalide)

Gastrointestinal Approved 1976-07-21

Kinevac is a diagnostic tool used in adults to assist with imaging and functional testing of the gallbladder, pancreas, and intestinal tract. It helps patients by triggering gallbladder contraction, which allows clinicians to analyze bile samples or view the organ through diagnostic imaging. Additionally, it is used to speed up the movement of barium through the small intestine to limit radiation exposure and can be used alongside secretin to evaluate pancreatic enzyme activity.

Source: FDA Label • BRACCO • Cholecystokinin Analog

How KINEVAC Works

As a cholecystokinin analog, the drug works by stimulating the gallbladder to contract and empty in a way that mimics the body's natural physiological response. It also increases intestinal motility and boosts the output of pancreatic secretions, which helps healthcare providers assess specific organ functions and accelerate the transit of imaging agents.

2
Indications
--
Phase 3 Trials
1
Priority Reviews
49
Years on Market

Details

Status
Prescription
First Approved
1976-07-21
Routes
INTRAVENOUS
Dosage Forms
POWDER

Companies

Active Ingredient: SINCALIDE

KINEVAC Approval History

1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
22 FDA actions from 1976 to 2023 · 1 indication expansions
Oct 2023 SUPPL
Label · Labeling
Dec 2018 SUPPL
Label · Labeling
Mar 2018 SUPPL
Label · Labeling

What KINEVAC Treats

3 indications

KINEVAC is approved for 3 conditions since its original approval in 1976. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Gallbladder contraction for imaging or bile analysis
  • Pancreatic secretion stimulation for functional analysis
  • Small bowel transit acceleration during barium imaging
Source: FDA Label

KINEVAC Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

2

Same indication, different mechanism — what else might this patient receive?

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT00706381 results posted 080165 08-DK-0165 Ph 3 completed Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

KINEVAC FDA Label Details

Indications & Usage

FDA Label (PDF)

KINEVAC is indicated for the treatment of Gallbladder contraction for imaging or bile analysis; Pancreatic secretion stimulation for functional analysis; Small bowel transit acceleration during barium imaging.

Track KINEVAC with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.